Neurology Service, Parc de Salut Mar, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
Clin Immunol. 2011 Dec;141(3):348-56. doi: 10.1016/j.clim.2011.09.006. Epub 2011 Sep 21.
CD56(bright) NK cells, which may play a role in immunoregulation, are expanded in multiple sclerosis (MS) patients treated with immunomodulatory therapies such as daclizumab and interferon-beta (IFNβ). Yet, whether this NK cell subset is directly involved in the therapeutic effect is unknown. As NK receptor (NKR) expression by subsets of NK cells and CD8+ T lymphocytes is related to MS clinical course, we addressed whether CD56(bright) NK cells and NKR in IFNβ-treated MS patients differ according to the clinical response. IFNβ was associated to lower LILRB1+ and KIR+NK cells, and higher NKG2A+NK cell proportions, an immunophenotypic pattern mainly found in responders. After IFNβ treatment, a CD56(bright) NK cell expansion was significantly related to a positive clinical response. Our results reveal that IFNβ may promote in responders changes in the NK cell immunophenotype, corresponding to the profile found at early maturation stages of this lymphocyte lineage.
CD56（bright）NK 细胞可能在免疫调节中发挥作用，在接受免疫调节治疗（如达利珠单抗和干扰素-β（IFNβ））的多发性硬化症（MS）患者中扩增。然而，这种 NK 细胞亚群是否直接参与治疗效果尚不清楚。由于 NK 细胞和 CD8+T 淋巴细胞亚群的 NK 受体（NKR）表达与 MS 临床病程有关，我们研究了 IFNβ 治疗的 MS 患者中 CD56（bright）NK 细胞和 NKR 是否根据临床反应而有所不同。IFNβ 与较低的 LILRB1+和 KIR+NK 细胞以及较高的 NKG2A+NK 细胞比例相关，这是一种主要在应答者中发现的免疫表型模式。IFNβ 治疗后，CD56（bright）NK 细胞的扩增与阳性临床反应显著相关。我们的结果表明，IFNβ 可能促进应答者 NK 细胞免疫表型的变化，与这种淋巴细胞谱系早期成熟阶段发现的特征相吻合。
